title: [Clinical evaluation of a combination treatment with cefbuperazone and amikacin in infections complicating with hematological disorders].
abstract: The efficacy and the safety of a combination regimen using cefbuperazone (CBPZ) and amikacin (AMK) were evaluated in severe infections in patients with hematological diseases. Twenty two patients were subjected to this combination therapy; among these, 18 patients were evaluable for the effectiveness. They included 9 cases of leukemia, 5 cases of malignant lymphoma, 2 cases of aplastic anemia, and 2 cases of angio-immunoblastic lymphadenopathy with dysproteinemia. Excellent responses were obtained in 5 patients and good responses in 5 patients, with a total effectiveness of 55.6%. Efficacy rates for individual types of infections were; 2/2 in sepsis, 6/14, or 42.9% in suspected sepsis, 1/1 in urinary tract infection, and and 1/1 in upper respiratory infection. The combination treatment was also effective in 4 of 6 cases in which neutrophil counts were less than 500/mm3 prior to therapy. Side effects were observed in only one patient. Mild proteinuria occurred in a 80-year-old male in 6 days after the regimen was started, but was not serious. These results indicate that a combination of CBPZ and AMK is safe and effective for the treatment of infections even in patients with compromised immunodefenses.
authors.affiliation: Third Department of Internal Medicine, Kyoto Prefectural University of Medicine.
authors.forename: S
authors.initials: S
authors.lastname: Tanaka
authors.forename: S
authors.initials: S
authors.lastname: Tsuda
authors.forename: H
authors.initials: H
authors.lastname: Nakagawa
authors.forename: H
authors.initials: H
authors.lastname: Nishigaki
authors.forename: T
authors.initials: T
authors.lastname: Okuda
authors.forename: M
authors.initials: M
authors.lastname: Taniwaki
authors.forename: S
authors.initials: S
authors.lastname: Misawa
authors.forename: T
authors.initials: T
authors.lastname: Takino
authors.forename: T
authors.initials: T
authors.lastname: Abe
mesh_terms: D000293:Adolescent; D000328:Adult; D000368:Aged; D000369:Aged, 80 and over; D000583:Amikacin / Q000008:administration & dosage* / Q000627:therapeutic use; D001424:Bacterial Infections / Q000188:drug therapy*; D002513:Cephamycins / Q000008:administration & dosage* / Q000627:therapeutic use; D004359:Drug Therapy, Combination; D005260:Female; D006402:Hematologic Diseases / Q000150:complications*; D006801:Humans; D007938:Leukemia / Q000150:complications; D008297:Male; D008875:Middle Aged; D012141:Respiratory Tract Infections / Q000188:drug therapy; D014552:Urinary Tract Infections / Q000188:drug therapy
chemical_list: D002513:Cephamycins; D000583:Amikacin; C035978:cefbuperazone